Innovotech Inc.
0.09
USD
+0.01
(+12.50%)
ISIN
CA45772U1049
CUSIP
45772U104
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Craig Milne
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Edmonton Canada
- IPO Date
- Mar 18, 2003
- Website
- innovotech.ca
- Similar Companies
- Business
- Innovotech Inc. is a Canadian biotechnology and contract research company that specializes in the research, development, and commercialization of proprietary antimicrobial and antibiofilm technologies, as well as specialized laboratory testing services for the healthcare, agricultural, and industrial sectors. Founded in 2001 and headquartered in Edmonton, Alberta, Canada, the company operates primarily through two core business segments: Contract Research Services and Proprietary Intellectual Property. Innovotech serves a global client base comprising medical device manufacturers, pharmaceutical corporations, biotechnology enterprises, academic institutions, and agricultural chemical producers across North America, Europe, and the Asia-Pacific region. The company offers a comprehensive portfolio of products and laboratory testing services, which includes: contract research organization (CRO) services delivering Good Laboratory Practice (GLP) compliant microbiological testing, antimicrobial efficacy assessments, medical device challenge testing, disinfectant evaluations, and custom assay design; the MBEC Assay kit, an ASTM-standardized (ASTM E2799) high-throughput device and assay system utilized worldwide for the rapid screening and quantification of antimicrobial compounds against microbial biofilms; the BEST Assay, a specialized testing platform designed for evaluating environmental surface biofilm susceptibility; InnovoSIL, a family of proprietary silver-based antimicrobial and antibiofilm compounds and surface coating technologies engineered for integration into medical devices, wound dressings, orthopedic implants, and catheters to prevent healthcare-associated infections; and Agress, a proprietary copper-based crop protection and seed treatment formulation designed to combat bacterial and fungal pathogens in agricultural crops. In recent corporate and operational developments, Innovotech has executed strategic initiatives to expand its biomedical assets, commercial capabilities, and laboratory capacity. The company completed the acquisition of Nou Life Sciences Inc., adding specialized intellectual property, dermatological technologies, and biomedical formulations to its proprietary asset portfolio. Furthermore, Innovotech expanded its contract research operations at its Edmonton facility by securing additional ISO/IEC 17025 laboratory accreditations and scaling its GLP-compliant testing infrastructure to support growing international demand from medical device and pharmaceutical developers. The company has also pursued strategic material transfer and licensing collaborations with global healthcare partners to advance the commercial integration of its InnovoSIL antimicrobial technology into clinical medical devices and therapeutic wound care applications.